Stover Angela M, Liang Debbie, Mueller Dana, Kurtzman Rachel, Ikemeh Christiana, Canter Courtney, Acharya Sonali, Brese Jill, Buhlinger Kaitlyn, Chen Kevin, Colmenares Evan W, Faso Aimee, Muluneh Benyam, Patel Bianka, Reichard Jeffrey S, Shah Rushabh M, Tilkens Michael, Valgus John, Coombs Lorinda A, Lafata Jennifer Elston, Lund Jennifer L, Ray Emily M, Mody Gita, Vest Mary-Haston
Department of Health Policy and Management, UNC Chapel Hill, Chapel Hill, NC, USA.
Lineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
Qual Life Res. 2025 Jan;34(1):201-217. doi: 10.1007/s11136-024-03789-8. Epub 2024 Oct 15.
Patient reported outcome measures (PROMs) are increasingly used in oncology care, but pharmacists providing direct patient care have been overlooked. We engaged pharmacists and adults receiving oral oncolytics (chemotherapy medication taken by mouth) to develop a SmartForm© in the electronic health record (EHR) for PROM monitoring. Pharmacists verbally ask the patient side effect questions during routine telehealth encounters and enter responses in real time.
Our development process was guided by the Knowledge to Action Framework. In phase 1 (Knowledge Inquiry), we prioritized side effects to assess in the EHR SmartForm© via interviews with patients and a Delphi panel with pharmacists. Adults receiving oral oncolytics for breast (n = 12), thoracic (n = 12), or hematological (n = 12) cancer were interviewed, with purposeful sampling for adults who were aged 65 + years or Black. Interviews were coded with content analysis. We conducted three Delphi rounds, with 11/19, 13/19, and 19/19 pharmacists, respectively. In phase 2 (Knowledge Synthesis), PROM items were selected and the EHR SmartForm© programmed. In phase 3 (Knowledge Tailoring), we conducted usability testing with pharmacists.
Pharmacists and patients were consistent in prioritizing side effects of oral oncolytics and 10 were retained. Patients advocated asking whether they can do their usual activities, while pharmacists added medication adherence. Usability testing yielded suggestions to simplify the SmartForm©.
By presenting screenshots of our SmartForm©, our findings are useful to other healthcare systems looking for a PROM solution integrated in the EHR, with a reasonable pharmacist/clinician workload, and no requirement for patients to have internet access/comfort.
患者报告结局测量(PROMs)在肿瘤护理中的应用日益广泛,但提供直接患者护理的药剂师却被忽视了。我们让药剂师和接受口服肿瘤药物(口服化疗药物)的成年人参与,在电子健康记录(EHR)中开发一个用于PROM监测的SmartForm©。药剂师在常规远程医疗会诊期间口头询问患者副作用问题,并实时输入回答。
我们的开发过程以知识转化为行动框架为指导。在第1阶段(知识探究),我们通过与患者访谈以及与药剂师组成的德尔菲小组,确定在EHR SmartForm©中要评估的副作用优先级。对接受口服肿瘤药物治疗乳腺癌(n = 12)、胸科肿瘤(n = 12)或血液系统肿瘤(n = 12)的成年人进行了访谈,对65岁及以上或黑人成年人进行了有目的抽样。访谈采用内容分析法进行编码。我们进行了三轮德尔菲调查,分别有11/19、13/19和19/19名药剂师参与。在第2阶段(知识综合),选择了PROM项目并对EHR SmartForm©进行编程。在第3阶段(知识调整),我们对药剂师进行了可用性测试。
药剂师和患者在确定口服肿瘤药物副作用的优先级方面意见一致,保留了10项。患者主张询问他们是否能够进行日常活动,而药剂师则增加了用药依从性方面的问题。可用性测试提出了简化SmartForm©的建议。
通过展示我们SmartForm©的屏幕截图,我们的研究结果对其他寻求将PROM解决方案集成到EHR中的医疗保健系统很有用,该解决方案具有合理的药剂师/临床医生工作量,并且患者无需具备互联网接入条件或相关操作能力。